September 25, 2025

To whom it may concern:

Company	D.Western Therapeutics Institute, Inc.
Representative	Yuichi Hidaka, President and CEO
	(Securities code: 4576; TSE Growth)
Contact	Sayako Matsubara, Director
TEL	052-218-8785

DW-5LBT “Bondlido” Approved in the US for the Treatment of Post-Herpetic Neuralgia

D. Western Therapeutics Institute, Inc. (“DWTI”) is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted marketing approval to DW-5LBT (Lidocaine (Note 1) patch, brand name: Bondlido) , which DWTI and MEDRx, Co., Ltd. (“MEDRx”) have jointly developed in the United States, for relief of pain associated with post-herpetic neuralgia (PHN) in adults.
Going forward, preparations for the launch will be made, including the selection of sales partners, with sales planned to begin in the US in the first half of 2026.

Although this matter will have no impact on the forecast for the fiscal year ending December 31, 2025, we believe that it will contribute to the improvement of earnings over the medium to long term.

Bondlido (development code: DW-5LBT)
Bondlido is a novel lidocaine patch that utilizes MEDRx’s proprietary ionic liquid transdermal system (ILTS®) technology and is being developed to address and expand the existing market for the Lidoderm® lidocaine patch. Based on the results of the clinical trials to date, Bondlido is expected to penetrate the market as a superior product to Lidoderm®, the leading benchmark product, with less skin irritation, superior adhesive strength, and retention of adhesive strength even during exercise. The US market for lidocaine patch products was estimated to be worth about USD 162 million in 2024 (date source : MEDRx).

End

Explanation of terms

(Note 1) Lidocaine
Lidocaine is a local anesthetic that reduces pain by blocking pain signals at nerve endings.